Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...

Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...

Under the deal, Sun Pharma will buy the outstanding shares ... 66% to Checkpoint’s closing share price last Friday, the Indian pharmaceutical giant said in a statement on Monday.

A new study reveals that generic drugs made in India are linked to a significantly higher number of severe adverse events, ...

Indian pharma CDMOs remain resilient, continuing to thrive due to favorable global factors. The B&K Securities report ...

New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...